Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients

Rheumatoid arthritis (RA) patients are currently treated with biological agents mostly aimed at cytokine blockade, such as tumor necrosis factor-alpha (TNFα). Currently, there are no biomarkers to predict therapy response to these agents. Here, we aimed to predict response to adalimumab (ADA) treatm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in immunology Jg. 14; S. 1303231
Hauptverfasser:	Hageman, Ishtu, Mol, Femke, Atiqi, Sadaf, Joustra, Vincent, Sengul, Hilal, Henneman, Peter, Visman, Ingrid, Hakvoort, Theodorus, Nurmohamed, Mike, Wolbink, Gertjan, Levin, Evgeni, Li Yim, Andrew Y.F., D’Haens, Geert, de Jonge, Wouter J.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland Frontiers Media S.A 22.12.2023
Schlagworte:	adalimumab Adalimumab - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - genetics Biomarkers DNA methylation Epigenome Humans Immunology machine learning rheumatoid arthritis therapy response Tumor Necrosis Factor-alpha DNA methylation machine learning rheumatoid arthritis therapy response adalimumab
ISSN:	1664-3224, 1664-3224
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!